Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
Diabetes & Metabolism Journal · 2024
DOI: 10.4093/dmj.2023.0314 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes & Metabolism Journal, 2024. Verfasst von Ji Hye Heo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea. Hauptthemen laut MEDLINE: Glucosides, Diabetes Mellitus, Type 2, Pioglitazone, Metformin. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jeil Pharmaceutical Co. Ltd..
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
This study assessed the efficacy and safety of triple therapy with pioglitazone 15 mg add-on versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and dapagliflozin.
Methods
In this multicenter, double-blind, randomized, phase 3 study, patients with T2DM with an inadequate response to treatment with metformin (≥1,000 mg/day) plus dapagliflozin (10 mg/day) were randomized to receive additional pioglitazone 15 mg/day (n=125) or placebo (n=125) for 24 weeks. The primary endpoint was the change in glycosylated hemoglobin (HbA1c) levels from baseline to week 24 (ClinicalTrials.gov identifier: NCT05101135).
Results
At week 24, the adjusted mean change from baseline in HbA1c level compared with placebo was significantly greater with pioglitazone treatment (–0.47%; 95% confidence interval, –0.61 to –0.33; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.
- Division of Endocrinology, Department of Internal Medicine, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Daegu Fatima Hospital, Daegu, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea.
Förderung
- Jeil Pharmaceutical Co. Ltd.
Zitieren
APA
Heo, J. H., Han, K. A., Hong, J. H., Seo, H. A., Hong, E. G., Yu, J. M., Jung, H. S., & Cha, B. S. (2024). Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2023.0314
Vancouver
Heo JH, Han KA, Hong JH, Seo HA, Hong EG, Yu JM, et al. Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial. Diabetes & Metabolism Journal. 2024. doi:10.4093/dmj.2023.0314
BibTeX
@article{Heo2024,
author = {Heo, Ji Hye and Han, Kyung Ah and Hong, Jun Hwa and Seo, Hyun-Ae and Hong, Eun-Gyoung and Yu, Jae Myung and Jung, Hye Seung and Cha, Bong-Soo},
title = {Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial},
journal = {Diabetes & Metabolism Journal},
year = {2024},
doi = {10.4093/dmj.2023.0314}
}
EUVIMED